SUPPLEMENTAL BALANCE SHEET INFORMATION

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Inventory consisted of the following:



	September 30, 2019		December 31, 2018
Raw materials	$	68,391	$	74,616
Work-in-process	321,073		231,064
Finished goods	219,585		225,191
Total inventory	$	609,049	$	530,871

Inventory as of September 30, 2019, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $7.1 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. The Company believes that all material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale have been significantly reduced. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If regulatory approval is not obtained, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed.

Accounts Payable and Accrued Liabilities consisted of the following:



	September 30, 2019		December 31, 2018
Accounts payable and accrued operating expenses	$	226,769	$	207,620
Accrued compensation expense	132,049		149,937
Accrued rebates payable	55,957		43,116
Accrued royalties payable	27,881		19,977
Value added taxes payable	7,556		7,785
Forward foreign currency exchange contracts	8,731		4,178
Lease liability	10,225		—
Other	14,577		4,677
Total accounts payable and accrued liabilities	$	483,745	$	437,290